Piper Sandler Reiterates Overweight on InspireMD, Lowers Price Target to $3
Benzinga Newsdesk 5 months ago
NewsPrice TargetReiterationAnalyst Ratings
Piper Sandler analyst Adam Maeder reiterates InspireMD (NASDAQ:NSPR) with a Overweight and lowers the price target from $4 to $3.
Piper Sandler analyst Adam Maeder reiterates InspireMD (NASDAQ:NSPR) with a Overweight and lowers the price target from $4 to $3.